Ultragenyx Pharmaceutical Inc. — All Filings
1,000 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-Q
10-Q/A
144
3
3/A
4
4/A
424B4
424B5
424B7
5
8-A12B
8-K
8-K/A
ARS
CERTNAS
CORRESP
CT ORDER
D
DEF 14A
DEFA14A
DRS
EFFECT
FWP
S-1
S-1/A
S-1MEF
S-3ASR
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SC TO-C
SC TO-T
SC TO-T/A
SCHEDULE 13G
SCHEDULE 13G/A
SEC STAFF LETTER
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 8-K | 8-K | 0000950170-25-094806 | Jul 9, 2025 | — |
| 8-K | 8-K | 0000950170-25-090616 | Jun 27, 2025 | — |
| 4 | 4 | 0000950170-25-088878 | Jun 23, 2025 | Jun 20, 2025 |
| 144 | — | 0001950047-25-004490 | Jun 20, 2025 | — |
| 4 | 4 | 0000950170-25-074662 | May 19, 2025 | May 15, 2025 |
| 4 | 4 | 0000950170-25-074661 | May 19, 2025 | May 15, 2025 |
| 4 | 4 | 0000950170-25-074666 | May 19, 2025 | May 15, 2025 |
| 4 | 4 | 0000950170-25-074664 | May 19, 2025 | May 15, 2025 |
| 4 | 4 | 0000950170-25-074665 | May 19, 2025 | May 15, 2025 |
| 4 | 4 | 0000950170-25-074667 | May 19, 2025 | May 15, 2025 |
| 4 | 4 | 0000950170-25-074669 | May 19, 2025 | May 15, 2025 |
| 8-K | 8-K | 0000950170-25-074529 | May 19, 2025 | May 15, 2025 |
| 10-Q | 10-Q | 0000950170-25-064726 | May 7, 2025 | Mar 31, 2025 |
| 8-K | 8-K | 0000950170-25-064473 | May 6, 2025 | — |
| 4 | 4 | 0000950170-25-063792 | May 5, 2025 | Apr 21, 2025 |
| SCHEDULE 13G/A | — | 0002052113-25-001563 | Apr 24, 2025 | — |
| DEF 14A | DEFINITIVE PROXY STATEMENT | 0001308179-25-000296 | Mar 28, 2025 | May 15, 2025 |
| DEFA14A | DEFINITIVE ADDITIONAL PROXY SOLICITING MATERIALS | 0001308179-25-000297 | Mar 28, 2025 | — |
| ARS | ANNUAL REPORT TO SECURITY HOLDERS | 0001308179-25-000298 | Mar 28, 2025 | Dec 31, 2024 |
| 4 | 4 | 0000950170-25-036056 | Mar 10, 2025 | Mar 6, 2025 |
| 4 | 4 | 0000950170-25-032802 | Mar 4, 2025 | Mar 1, 2025 |
| 4 | 4 | 0000950170-25-032767 | Mar 4, 2025 | Mar 1, 2025 |
| 4 | 4 | 0000950170-25-032764 | Mar 4, 2025 | Mar 1, 2025 |
| 4 | 4 | 0000950170-25-032785 | Mar 4, 2025 | Mar 1, 2025 |
| 4 | 4 | 0000950170-25-032773 | Mar 4, 2025 | Mar 1, 2025 |
| 4 | 4 | 0000950170-25-032779 | Mar 4, 2025 | Feb 28, 2025 |
| 4 | 4 | 0000950170-25-032794 | Mar 4, 2025 | Mar 1, 2025 |
| 4 | 4 | 0000950170-25-032750 | Mar 4, 2025 | Mar 1, 2025 |
| 4 | 4 | 0000950170-25-032798 | Mar 4, 2025 | Mar 1, 2025 |
| 4 | 4 | 0000950170-25-030639 | Mar 3, 2025 | Feb 27, 2025 |
| 144 | — | 0002007317-25-000222 | Feb 28, 2025 | — |
| 144 | — | 0001972362-25-000193 | Feb 27, 2025 | — |
| 10-K | 10-K | 0000950170-25-023312 | Feb 19, 2025 | Dec 31, 2024 |
| 8-K | 8-K | 0000950170-25-019854 | Feb 13, 2025 | — |
| SCHEDULE 13G/A | — | 0001020066-25-000013 | Feb 12, 2025 | — |
| SCHEDULE 13G/A | — | 0000902219-25-000076 | Feb 10, 2025 | — |
| 8-K | 8-K | 0000950170-25-004587 | Jan 13, 2025 | Jan 12, 2025 |
| 4 | 4 | 0000950170-24-141485 | Dec 31, 2024 | Dec 30, 2024 |
| 144 | — | 0001971857-24-000911 | Dec 30, 2024 | — |
| 8-K | 8-K | 0000950170-24-138250 | Dec 19, 2024 | — |
| 8-K | 8-K | 0000950170-24-138467 | Dec 19, 2024 | — |
| 4 | 4 | 0000950170-24-135521 | Dec 11, 2024 | Dec 9, 2024 |
| 4 | 4 | 0000950170-24-135525 | Dec 11, 2024 | Dec 10, 2024 |
| 144 | — | 0001971857-24-000811 | Dec 10, 2024 | — |
| SC 13G/A | ULTRAGENYX PHARMACEUTICAL INC. | 0000902664-24-006498 | Nov 14, 2024 | — |
| 8-K | 8-K | 0000950170-24-124458 | Nov 12, 2024 | Nov 9, 2024 |
| 10-Q | 10-Q | 0000950170-24-121679 | Nov 6, 2024 | Sep 30, 2024 |
| 8-K | 8-K | 0000950170-24-121459 | Nov 5, 2024 | — |
| 4 | 4 | 0000950170-24-114378 | Oct 11, 2024 | Oct 10, 2024 |
| 8-K | 8-K | 0000950170-24-113085 | Oct 7, 2024 | — |